drugset / Trial / NCT00264667

Study In Patients With Dyslipidaemia

NCT00264667

Phase 2 Completed 290 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

Study in patients with dyslipidaemia.

Timeline

Start
2005-12
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SODELGLITAZAR Small molecule 2.5 mg Oral
Subject SODELGLITAZAR Small molecule 5 mg Oral
Subject SODELGLITAZAR Small molecule 10 mg Oral
Subject SODELGLITAZAR Small molecule 20 mg Oral

Indications